Identify the mechanisms of liver fibrosis and liver cancer"Expect research and development of new treatments"
Aug 06, 2024
The results of molecular mechanism research and the function of 'Galectin 3-binding protein (LGALS3BP)' in liver fibrosis and liver cancer presented by a research team led by Professor Jeong Ik-joo of Oncology Department at Hwasun Chonnam National University Hospital are drawing attention.
Hwasun Chonnam National University Hospital said that Professor Jeong Ik-ju's research team's research on reducing the availability of transgenic growth factor-beta (TGF-β1) through the removal of 'Galectin 3-Binding Protein (LGALS3-BP) alleviated liver fibrosis and suppressed the occurrence of liver cancer (LGALS3BP) depletionattenuates hepatic fibrosis by reducing the incidence of liver cancer (TGF-β1) availability and inhibits hepatocarcinogenesis)' is a renowned international journal.1) It was announced on July 5 that it was published in the online edition of July 28.
In particular, the research team was finally selected by the Biological Research Information Center (BRIC) 'People who Shined Korea (Hanbitsa Temple)' with this paper. BRIC selects and introduces academic journals with an Impact Factor of 10 or higher or within the top 3% of each group based on JCR as 'Hanbitsa'.
The research team found a close correlation between LGALS3BP and transgenic growth factor-beta gene expression in patients with metabolic abnormal steatohepatitis (MASH) and liver cancer and succeeded in identifying the mechanisms related to it.
In addition, it was confirmed that LGALS3BP induced the relocation of the F-actin cytoskeleton through direct binding with integrin αV in hepatocytes, and that the tension generated through this caused TGF-beta secretion, eventually leading to liver fibrosis and liver cancer.
In addition, it was also found that the removal of the LGALS3BP gene reduces the incidence of steatohepatitis and liver cancer.
Professor Lee Ik-joo, Director of the National Center for Immunotherapy Innovation, "This study suggested LGALLS3BP as a new target for treating TGF-beta-related liver fibrosis and liver cancer, and it could be expanded into research on the development of new liver fibrosis and liver cancer treatments that can control LGALLS3BP in the future."."
Meanwhile, this study was carried out with the support of the National Immunotherapy Platform Establishment Project (National Immunotherapy Innovation Center) and Basic Research Project (Composite Cancer Immunotherapy Center) promoted by the Ministry of Science and ICT and the Korea Research Foundation.
Hwasun Chonnam National University Hospital said that Professor Jeong Ik-ju's research team's research on reducing the availability of transgenic growth factor-beta (TGF-β1) through the removal of 'Galectin 3-Binding Protein (LGALS3-BP) alleviated liver fibrosis and suppressed the occurrence of liver cancer (LGALS3BP) depletionattenuates hepatic fibrosis by reducing the incidence of liver cancer (TGF-β1) availability and inhibits hepatocarcinogenesis)' is a renowned international journal.1) It was announced on July 5 that it was published in the online edition of July 28.
In particular, the research team was finally selected by the Biological Research Information Center (BRIC) 'People who Shined Korea (Hanbitsa Temple)' with this paper. BRIC selects and introduces academic journals with an Impact Factor of 10 or higher or within the top 3% of each group based on JCR as 'Hanbitsa'.
The research team found a close correlation between LGALS3BP and transgenic growth factor-beta gene expression in patients with metabolic abnormal steatohepatitis (MASH) and liver cancer and succeeded in identifying the mechanisms related to it.
In addition, it was confirmed that LGALS3BP induced the relocation of the F-actin cytoskeleton through direct binding with integrin αV in hepatocytes, and that the tension generated through this caused TGF-beta secretion, eventually leading to liver fibrosis and liver cancer.
In addition, it was also found that the removal of the LGALS3BP gene reduces the incidence of steatohepatitis and liver cancer.
Professor Lee Ik-joo, Director of the National Center for Immunotherapy Innovation, "This study suggested LGALLS3BP as a new target for treating TGF-beta-related liver fibrosis and liver cancer, and it could be expanded into research on the development of new liver fibrosis and liver cancer treatments that can control LGALLS3BP in the future."."
Meanwhile, this study was carried out with the support of the National Immunotherapy Platform Establishment Project (National Immunotherapy Innovation Center) and Basic Research Project (Composite Cancer Immunotherapy Center) promoted by the Ministry of Science and ICT and the Korea Research Foundation.
|
bellho@sportschosun.com
